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Abstract
Background: Identifying functional non-coding variation is critical for defining the genetic contributions to human
disease. While single-nucleotide polymorphisms (SNPs) within cis-acting transcriptional regulatory elements have
been implicated in disease pathogenesis, not all cell types have been assessed and functional validations have been
limited. In particular, the cells of the peripheral nervous system have been excluded from genome-wide efforts to
link non-coding SNPs to altered gene function. Addressing this gap is essential for defining the genetic architecture
of diseases that affect the peripheral nerve. We developed a computational pipeline to identify SNPs that affect
regulatory function (rSNPs) and evaluated our predictions on a set of 144 regions in Schwann cells, motor neurons,
and muscle cells.
Results: We identified 28 regions that display regulatory activity in at least one cell type and 13 SNPs that affect
regulatory function. We then tailored our pipeline to one peripheral nerve cell type by incorporating SOX10 ChIP-
Seq data; SOX10 is essential for Schwann cells. We prioritized 22 putative SOX10 response elements harboring a
SNP and rapidly validated two rSNPs. We then selected one of these elements for further characterization to assess
the biological relevance of our approach. Deletion of the element from the genome of cultured Schwann
cells—followed by differential gene expression studies—revealed Tubb2b as a candidate target gene. Studying
the enhancer in developing mouse embryos revealed activity in SOX10-positive cells including the dorsal root
ganglia and melanoblasts.
Conclusions: Our efforts provide insight into the utility of employing strict conservation for rSNP discovery.
This strategy, combined with functional analyses, can yield candidate target genes. In support of this, our
efforts suggest that investigating the role of Tubb2b in SOX10-positive cells may reveal novel biology within
these cell populations.
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Background
The identification of functional genetic variation is critical
for understanding the allelic, locus, and clinical heterogen-
eity of human inherited disease. Genome-wide association
studies (GWAS) have identified common variants in non-
coding sequences—including transcriptional regulatory ele-
ments—that have implications for defining disease-causing
and disease-modifying variants [1]. A major challenge re-
mains in understanding the functional consequences of the
implicated variants, which are frequently single-nucleotide
polymorphisms (SNPs). Predicting the functional effects of
SNPs is difficult due to many factors including limited
knowledge of cis-acting regulatory elements (CREs) and an
incomplete vocabulary of transcription factor binding sites
(TFBS), especially in understudied cell populations. Fur-
thermore, it is difficult to predict the location of CREs as
they may reside anywhere in the genome and millions of
base pairs distal to the genes that they regulate [2]. While
ENCODE improved our TFBS vocabulary and, as a conse-
quence, our understanding of functional genetic variation,
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many tissue types have not been assessed and many of
these predictions have not been functionally validated [3].
The ability to predict the effect of non-coding variation on
gene expression and rapidly validate genomic regions for
cis-regulatory activity will aid the identification of modifiers
of human disease [4].
Charcot-Marie-Tooth (CMT) disease displays vast clin-
ical heterogeneity and variable penetrance. CMT is an
inherited peripheral neuropathy that affects 1 in 2500
individuals worldwide and is characterized by impaired
motor and sensory nerve function in the distal extremities
[5]. CMT is subdivided into two major classes: demye-
linating (CMT1) and axonal (CMT2) [6]. CMT1 affects
Schwann cell myelination and, predictably, genes asso-
ciated with CMT1, including myelin protein zero
(MPZ) [7, 8] and peripheral myelin protein 22 (PMP22)
[9, 10], are critical for that process. Similarly, the genes
implicated in CMT2, which affects motor and sensory
axons, include neurofilament light chain (NEFL) [11]
and mitofusin 2 (MFN2) [12], which are critical for
axon function. Interestingly, while over 80 genes have
been implicated in CMT disease [13], phenotypic vari-
ability is observed even among patients with a molecu-
larly indistinguishable mutation. For example, patients
with a duplication of PMP22 have variable age of onset
(3-73 years of age), variable motor and sensory nerve
involvement, and display a broad spectrum of severity,
ranging from mild difficulty in walking or running to
impairment requiring a wheelchair [14].
Among genetic variants that may modify human disease
phenotypes, regulatory SNPs (rSNPs) present a unique
challenge. Single-base-pair changes within sequence space
that lacks a vocabulary leave few clues to their influence.
rSNPs typically reside within transcriptional regulatory
elements and have allele-specific effects on gene expres-
sion. An rSNP may increase regulatory activity as demon-
strated by the rSNP within an enhancer at NOS1AP that
elevates risk of cardiac arrhythmias [15]. Conversely,
rSNPs may decrease regulatory activity as observed at
SH3TC2, where the minor allele greatly reduces the bind-
ing ability of CREB [16]. Finally, an rSNP may create a
novel TFBS as observed within the TNF promoter region,
which results in the establishment of an OCT-1 binding
site and increased gene expression [17]. While the cause
of clinical variability within CMT disease is unknown, one
possibility is that rSNPs, likely within TFBSs, may affect
gene function in the cells of the peripheral nerve and
exacerbate or alleviate the disease phenotype. Consistent
with this notion, mutations in the promoter of GJB1 cause
CMT disease [18]. A subset of GJB1 promoter muta-
tions disrupt binding of the transcription factor
SOX10, which is critical for Schwann cell development
and function; SOX10 directly regulates genes import-
ant for Schwann cells and that have been implicated in
demyelinating CMT disease (e.g., MPZ, GJB1, and
PMP22) [19–21].
Here, we describe a genome-wide search for rSNPs with
potential relevance to the peripheral nerve. We developed
a computational pipeline to identify human non-coding
genomic sequences that harbor a SNP with a major allele
that is conserved among diverse vertebrate species:
human, mouse, and chicken. Subsequently, we undertook
a pilot functional evaluation of a subset of conserved gen-
omic segments via luciferase assays in three cell lines rele-
vant to the peripheral nerve and CMT disease: Schwann
cells, motor neurons, and muscle cells. Finally, we deeply
characterized one validated rSNP, demonstrating that it
resides in a SOX10-responsive CRE that may regulate
Tubb2b, which is mutated in patients with asymmetric
polymicrogyria [22]. Interestingly, our results show that
strict conservation analyses may not consistently enrich
for CREs and associated rSNPs, thus underscoring the
employment of complementary approaches.
Results
Genome-wide computational predictions of regulatory
SNPs (rSNPs)
To identify and prioritize a set of putative CREs that
harbor rSNPs, we developed a novel computational pipe-
line (Fig. 1). First, the human (hg18), mouse (mm9), and
chicken (Gal3) genomes were downloaded from the
UCSC Genome Browser [23], aligned using MultiPip-
Maker [24], and the alignments analyzed using ExactPlus
[25] to identify genomic segments that are identical
among the three species and at least five base pairs in
length [26]. Next, conserved regions overlapping a SNP
that was ‘validated by-frequency’ [i.e., SNPs that were
submitted (dbSNP 130) with allele frequency informa-
tion] were identified to generate a panel of conserved
regions harboring a SNP. A similar analysis was per-
formed using dbSNP 142 (Additional file 1: Figure S1).
Finally, regions that overlapped exons (≥1 bp) were
removed using the RefSeq database. The above process
established a panel of 6197 SNPs that reside within 6164
conserved, non-coding sequences (Additional file 2).
Identification of enhancers relevant to the peripheral
nerve
To validate the efficacy of our computational approach, we
selected a set of 160 regions (~ 2.5% of the total dataset;
Additional file 3), which includes all genomic segments
harboring a SNP that we identified on chromosome X (94
regions), chromosome 22 (29 regions), and chromosome
21 (37 regions). To functionally assess these 160 genomic
segments, we tested each for the ability to direct luciferase
reporter gene expression in vitro using immortalized cell
lines relevant to the peripheral nerve: Schwann cells (S16),
motor neurons (MN1), and muscle cells (myoblasts;
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C2C12). S16 cells are an immortalized rat Schwann cell
line that expresses myelin-associated genes (e.g., MAG,
MPZ, and PMP22) and transcription factors (e.g. SOX10
and EGR2) [27, 28]. MN1 cells were generated by somatic
cell fusion between mouse spinal motor neurons and
mouse neuroblastoma cells and exhibit traits similar to
motor neurons including the ability to form neurite projec-
tions [29]. C2C12 cells are a mouse muscle progenitor cell
line [30] that can be differentiated into muscle cells [31].
This process is incomplete, however, resulting in a hetero-
geneous population of cells and yielding transfection data
that are difficult to interpret. Therefore, we focused our
analyses on S16 and MN1 cell lines, but include the C2C12
data as supplemental material since they represent a critical
tissue for peripheral nerve diseases. Briefly, each putative
enhancer harboring the major SNP allele (Additional file 3)
was cloned upstream of a minimal promoter directing lucif-
erase gene expression [25]. Sequences surrounding each
conserved region were selected based on the PhastCons
17-way vertebrate alignment dataset (mean = 885 bp, range
= 105 bp to 2497 bp) [32]. The selected sequences were
then separately transfected into each cell line, and luciferase
activity was measured relative to a control vector with no
genomic insert. Regions demonstrating a greater than five-
fold increase in luciferase activity relative to the control
vector were considered to have ‘strong’ activity and were se-
lected for further analyses.
We successfully cloned 144 of the 160 genomic segments
in our pilot study. Of the 16 regions lost: one SNP was re-
moved in updated databases and was excluded from fur-
ther analysis, six were amplified along with another region
in the same PCR product, eight could not be amplified, and
one could not be cloned. The regions were named SNP
Conservation (“SC”) followed by the chromosome and
were numbered from the p-arm to the q-arm. For example,
SCX-1 is the most distal region identified on the p-arm of
chromosome X. Each of the 144 putative enhancers was
subjected to Sanger sequencing to verify the presence of
the major allele and then transfected into S16, MN1, and
C2C12 cell lines. The activity of each region was assessed
in both the forward and reverse orientation with respect to
the minimal promoter. Of the 144 regions tested in S16
cells, 13 demonstrated ‘strong’ luciferase activity in at least
one orientation: SCX-3, SCX-4, SCX-21, SCX-39, SCX-58,
SCX-60, SCX-65, SCX-67, SCX-78, SCX-81, SC21-13,
SC21-16, and SC21-20 (Fig. 2a and Table 1). In experi-
ments using MN1 cells, 11 of the 144 regions demon-
strated ‘strong’ luciferase activity in at least one orientation:
SCX-3, SCX-4, SCX-21, SCX-45, SCX-58, SCX-60, SCX-63,
SC21-10, SC21-12, SC22-1, and SC22-8 (Fig. 2b and Table
1). In experiments using differentiated C2C12 cells, 21 of
the 144 regions demonstrated ‘strong’ luciferase activity in
at least one orientation: SC21-10, SC21-16, SC21-18,
SC21-27, SC21-33, SC21-34, SC22-1, SC22-8, SC22-14,
SCX-3, SCX-4, SCX-18, SCX-20, SCX-21, SCX-33, SCX-45,
SCX-52, SCX-58, SCX-60, SCX-63, and SCX-67 (Add-
itional file 4: Figure S2 and Table 1). In sum, we identified
28 unique regions with strong luciferase activity in at least
one orientation in Schwann cells, motor neurons, and/or
muscle cells. While we did not exclude conserved regions
harboring multiple SNPs, no such element exceeded our
threshold for activity in the above experiments.
The minor alleles of eight peripheral nerve enhancers
significantly reduce regulatory activity
The 13 genomic segments active in Schwann cells, the 11
genomic segments active in motor neurons, and the 21
genomic segments active in muscle cells were mutagenized
to the minor allele and reassessed in the respective cell line
to test for allele-specific differences in regulatory activity.
Each allele was tested in both orientations (forward and re-
verse, relative to the minimal promoter) regardless of the
endogenous orientation with respect to the predicted target
gene. In reporting these data, the more active allele of each
Fig. 1 A computational pipeline to identify putative regulatory SNPs.
The human, mouse, and chicken genomes were aligned, and genomic
segments five base-pairs in length or greater and identical in all three
species were identified to compile a panel of multiple-species conserved
sequences (MCSs). Overlap between the MCS dataset and validated
‘by-frequency’ SNPs from db SNP130 was determined. Exons were
excluded using RefSeq entries, and a pilot set of 160 regions were
identified on chromosomes 21, 22, and X. The number of regions
in each resulting dataset are indicated below the label
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region was set to ‘100%’, and the activity of the less active al-
lele was expressed relative to the more active allele. In
Schwann cells, SC21-13, SCX-4, SCX-58, SCX-60, SCX-67,
SCX-78, and SCX-81 displayed allele-specific differences in
luciferase activity (Fig. 3a, b, and Table 1). In motor neu-
rons, SC21-10, SCX-4, SCX-58, and SCX-60 displayed
allele-specific differences in luciferase activity (Fig. 3c, d,
and Table 1). In C2C12 cells, SC21-18, SC21-27, SC22-8,
SCX-4, SCX-21, SCX-45, and SCX-67 displayed allele-
specific differences in luciferase activity (Additional file 5:
Figure S3). Combined, we identified 13 unique regions
displaying significant allele-specific differences in regulatory
activity between the major and minor alleles. Three regions
were unique to S16 cells, one region was unique to MN1
cells, and five regions were unique to C2C12 cells, while
the remaining four regions demonstrated reduced regula-
tory activity in a combination of cells (Table 1).
Predicting differential transcription factor binding to
active regions
One possible explanation for the allele-specific dif-
ferences described above is that the SNP alleles
a
b
Fig. 2 Activity of a pilot set of putative regulatory elements on chromosomes 21, 22, and X in Schwann cells and motor neurons. 144 genomic
regions containing the major SNP allele were cloned upstream of a luciferase reporter gene and tested in the forward (blue bars) or reverse (red bars)
orientation in S16 (a) and MN1 cells (b). The activity of each genomic segment is expressed relative to a control vector with no genomic insert (first
bar in each frame). Dashed lines indicate a five-fold increase in activity over the control vector, and error bars show standard deviations
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display differential affinity for transcription factors.
To test this possibility, we used an in silico tran-
scription factor binding site prediction program,
TRANSFAC [33]. Sequence fragments of 30 base
pairs centered around each major SNP allele were
generated. The major allele was swapped for the











SC21-12 9.95 (M) 5.34 (M) chr21:22,535,874-22,535,880 rs2827297






SC21-18 1.37 (C) 8.90 (C) chr21:33,139,128-33,139,135 rs2833975
SC21-20 5.81 (S) 5.04 (S) chr21:33,273,214-33,273,219 rs2834040
SC21-27 16.05 (C) 4.71 (C) chr21:36,269,198-36,269,214 rs2835196
SC21-33 13.85 (C) 3.40 (C) chr21:38,940,551-38,940,556 rs16996658


























SCX-18 14.59 (C) 0.98 (C) chrX:31,252,044-31,252,049 rs7884417








SCX-33 0.67 (C) 13.92 (C) chrX:85,443,058-85,443,064 rs6623642
































SCX-78 5.21 (S) 5.80 (S) chrX:146,960,885-146,960,891 rs6525876
SCX-81 1.09 (S) 12.85 (S) chrX:147,430,625-147,430,635 rs17252118
aActivity only shown for cell line(s) where region was active
S = S16, M =MN1, C = C2C12
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minor allele and both sequences were submitted to
TRANSFAC. The sequences were assessed for TFBS
predictions using the TRANSFAC Match algorithm
and the vertebrate database of transcription factors,
minimizing the sum of false positive and false nega-
tive errors. Results were filtered to display only unique
differences in predicted TFBSs, which may explain the
differential activity.
For the seven genomic segments differentially active
in Schwann cells (Fig. 4a-d and f-h), each had at least
one allele-specific TFBS prediction. Interestingly, none
of the four Schwann cell specific regions [SC21-13,
SCX-67, SCX-78, and SCX-81 (Fig. 4a-d)] harbored pre-
dicted TFBSs known to be important for these cells.
While these results may be due to the limitations of
TRANSFAC, they may also illustrate potentially novel
roles of the predicted transcription factors in Schwann
cells. For the four genomic segments differentially
active in motor neurons (Fig. 4e-h), one (SC21-10)
displayed no allele-specific predictions (Fig. 4e). This
result may indicate that the SNP does not ablate or
alter TFBS binding affinity or it may reflect the incom-
plete nature of TFBS databases. For the seven genomic
segments differentially active in muscle cells
(Additional file 6: Figure S4), each had at least one
allele-specific TFBS prediction; two of these segments
demonstrated regulatory activity only in muscle cells
(SC21-18 and SC21-27). Strikingly, a LEF-1 binding site
prediction is unique to the minor allele of SC21-27.
Lef-1 expression increases in mouse muscle cells
following muscle injury [34]. Our data show that the
minor allele of SC21-27 demonstrates significantly
lower regulatory activity compared to the major allele
(Additional file 5: Figure S3). Indeed, LEF-1 can act as
a transcriptional repressor [35, 36] suggesting that the
increased activity of the major allele is due to decreased
LEF-1 binding; however, further study is needed to
determine the role of the putative LEF-1 binding site in
regulatory activity. Taken together, TRANSFAC re-
vealed differential TFBS predictions across many of the
genomic segments showing allele-specific differences in
regulatory activity. While the significance of these pre-
dictions vary with respect to what is known about
Schwann cell, motor neuron, and muscle cell biology,
some may represent novel findings relevant to gene





Fig. 3 Eight genomic regions display allele-specific differences in regulatory activity in Schwann cells and motor neurons. a and b The activ-
ity of the major (black bars) and minor (grey bars) alleles of the 13 regions active in Schwann cells (Fig. 2) were evaluated in the forward (a)
or reverse (b) orientation. c and d The major and minor alleles of the 11 genomic segments active in MN1 cells were compared as in panels
a and b. In all panels, the allele with higher luciferase activity was set to “100”, error bars represent standard deviations, bold and underlined
text indicate the orientation(s) that were active in the experiments shown in Fig. 2, and asterisks indicate a significant change in
activity (p ≤ 0.05)
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Identification of two rSNPs within SOX10 response
elements
Our pipeline successfully identified a small panel of pu-
tative rSNPs in a transcription-factor-independent ap-
proach. We next wanted to evaluate our computational
predictions in the context of TFBS information (i.e.,
motif analysis and ChIP-Seq data). To this end, we evalu-
ated the conserved regions, identified above, harboring a
SNP from dbSNP 130 (6164 regions; Fig. 1 and Additional
file 2) for the presence of a predicted SOX10 binding site
(Fig. 5a). SOX10 was chosen because it is critical for
Schwann cell function and regulates genes involved in
peripheral nerve myelination [19–21]. SOX10 also directly
binds to DNA via a well-defined consensus sequence as
either a monomer or as a dimer when two monomeric
sequences are oriented in a head-to-head fashion [37–39].
We first identified all SOX10 monomeric consensus
sequences within the human genome [5′ to 3′: ACAAA,
ACACA, ACAAT, or ACAAG (and the reverse comple-
ment of each)]. We then overlapped these data with the
conserved regions harboring a SNP, which revealed 224
putative monomeric SOX10 binding sites containing a
SNP and conserved among human, mouse, and chicken
(Additional file 7). This dataset was further prioritized by
only including sequences that overlap with SOX10 ChIP-
Seq data [39] [resulting in nine regions, referred to as
rSNP-containing and SOX10-relevant (rSOX) 1 through 9
in Fig. 5a and Table 2] and by separately assessing for the
presence of a dimeric SOX10 consensus sequence where
both monomers were conserved, but only one monomer
was required to contain a SNP (resulting in 13 regions, re-
ferred to as rSOX-10 through 22 in Fig. 5a and Table 2).
The major allele of each of the 22 rSOX regions was
cloned and evaluated for regulatory activity in S16 cells
via luciferase assays as described above; SOX10 and
SOX10 target genes are expressed in S16 cells [40].
Sequences surrounding each conserved rSOX region
was selected for cloning based on the PhastCons 17-way
vertebrate alignment dataset (mean = 729 bp, range =
319 bp to 1834 bp) [32]. These efforts revealed four
genomic segments that exceeded a five-fold threshold of
activity in at least one orientation: rSOX-1, rSOX-4,
rSOX-6, and rSOX-22 (Fig. 5b and c, and Table 3). To
assess for allele-specific differences in regulatory activity,
the four genomic segments with strong activity were
mutagenized to the minor allele and reassessed in lu-
ciferase assays in S16 cells. Two regions, rSOX-4 and
rSOX-22, showed a significant difference in luciferase
activity between the two alleles (Fig. 6a). The minor
allele of rSOX-4 demonstrated 45.8% of the activity
compared to the major allele, and the minor allele of
rSOX-22 demonstrated 57.0% of the activity of the
major allele.
We further assessed the role of SOX10 in regulating
rSOX-4 and rSOX-22 by deleting the putative SOX10 bind-
ing sites harboring a SNP (a single monomeric sequence
for rSOX-4 and a single dimeric sequence for rSOX-22)
and performing luciferase activity assays in S16 cells. In
each case we observed an even more dramatic decrease in
regulatory activity upon deleting the SOX10 binding site.
Relative to the major alleles, rSOX-4 ΔSOX demonstrated









Fig. 4 TRANSFAC predictions of transcription factor binding sites.
TRANSFAC was used to assess for differential TFBS predictions between
the major and minor alleles of SNP alleles that had a significant effect
on luciferase activity. Results are shown for four regions active only in
S16 cells [SC21-13 (a), SCX-67 (b), SCX-78 (c), and SCX-81 (d)], one
region active only in MN1 cells [SC21-10 (e)], and three regions active
in both cell types [SCX-4 (f), SCX-58 (g), and SCX-60 (h)]. Thirty base
pairs surrounding the SNP alleles of each region were submitted to
TRANSFAC. Dashed arrows indicate the position and direction of the
predicted TFBS, the name of the transcription factor is indicated above
each arrow, and the core and matrix scores are indicated at the right.
Only allele-specific TFBS predictions are displayed. Underlined base
pairs indicate conserved bases, and SNP alleles are highlighted in red
and bold text
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activity (Fig. 6b). We also tested each SNP allele and
ΔSOX10 genomic segment for activity in MN1 cells, which
do not express endogenous SOX10. Neither region harbor-
ing the major allele showed strong activity in MN1 cells,
consistent with SOX10 being required for the observed
regulatory activities (Fig. 6b). Furthermore, neither the
minor SNP allele nor deletion of the SOX10 consensus
sequence had an effect on regulatory activity in SOX10-
negative MN1 cells.
We next evaluated the role of SOX10 in regulating
rSOX-4 and rSOX-22 by studying the activity of each
allele in SOX10-negative MN1 cells co-transfected with a
construct to overexpress wild-type SOX10. In the absence
of SOX10, neither allele of the two regions demonstrated
activity in MN1 cells, consistent with the results above. In
contrast, in the presence of SOX10, both regions displayed
strong activity, approximately 200-fold and 89-fold higher
for rSOX-4 and rSOX-22, respectively (Fig. 6c). Con-
versely, when we performed luciferase assays with a con-
struct to express a dominant-negative SOX10 protein
(E189X) to deplete endogenous SOX10 function in S16
cells [41], both regions displayed severely decreased
activity (~ 9%) compared to the respective major alleles
(Fig. 6d). Taken together, our data indicate that SOX10 is
both necessary and sufficient for the in vitro regulatory ac-
tivity of rSOX-4 and rSOX-22 in cultured Schwann cells.
Ablation of rSOX-4 in cultured Schwann cells reduces
Tubb2b expression
Identifying the target gene(s) of cis-acting regulatory
elements is essential for understanding the biological
significance of rSNPs that reside within these elements.
To identify the target gene of an enhancer/rSNP pair
identified in this study, we selected rSOX-4 and deleted
it from S16 cells using CRISPR/Cas9 [42] technology.
We then performed RNA-Seq analysis in an unbiased
attempt to identify candidate target genes with altered
expression. The rSOX-4 element is a 651-base-pair re-
gion that resides in a ~ 1 Mb interval devoid of anno-
tated genes (Additional file 8: Figure S5A) and that
displayed genomic features indicating that it is an ac-
tive, SOX10-bound enhancer, including: H3K27 acetyl-
ation from adult rat peripheral nerve [43], SOX10
ChIP-Seq from P15 rat sciatic nerve [39], and DNase
hypersensitivity from the S16 cell line [26] (Additional
file 8: Figure S5A). Briefly, repair templates were gener-
ated with ~ 1 Kb arms of homology to the 5′ and 3′ re-
gions surrounding the 651-base-pair rSOX-4 element,
and flanking a floxed blasticidin (or neomycin) resist-
ance cassette (Fig. 7a). S16 cells were transfected with
the blasticidin repair template, human codon optimized
Cas9 (hCas9), and one of two gRNAs targeting rSOX-4
(Additional file 9: Figure S6). Next, cells were selected
a b
c
Fig. 5 Identification of putative SOX10 response elements in Schwann cells. a All SOX10 consensus sequences in the human genome were identified, and
these data were intersected with multiple-species conserved sequences (MCSs; see text for details). Overlap between the conserved SOX10 monomers and
SNPs validated ‘by-frequency’ from dbSNP 130 was determined, and exons were excluded using RefSeq entries. This dataset of conserved, non-coding
SOX10 monomers harboring a SNP was prioritized by identifying regions overlapping SOX10 ChIP-Seq data or by identifying a dimeric SOX10 consensus
sequence. The number of regions in each resulting dataset is indicated under the label. b and c The 22 genomic segments from panel A were cloned
upstream of a luciferase reporter gene and tested in the forward (b; blue bars) and reverse (c; red bars) orientation in SOX10-positive S16 cells. The activity
of each genomic segment is expressed relative to a control vector with no genomic insert (‘Empty’ in b and c). Four regions displayed greater than five-
fold activity (indicated by the dashed line) in at least one orientation. Error bars indicate standard deviations
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for stable and proper integration of the blasticidin re-
pair template and flow sorted to generate clonal cell
lines. We generated two clones, one using gRNA-1
(rSOX-4 Clone 1-B) and one using gRNA-2 (rSOX-4
Clone 2-B) that had proper integration of the blastici-
din resistance repair cassette. Integration was assessed
using a diagnostic PCR with one primer outside the tar-
geting vector and one primer within the drug repair
template. These PCR products were sequence verified
to ensure the integrity of the genomic DNA. This
process was repeated once more using the neomycin
resistance template to generate double-resistant clonal
cell lines with no wild-type alleles at rSOX-4 (Fig. 7b).
Clones were then transiently transfected with a Cre:
GFP expression construct to remove the drug resist-
ance cassettes, and GFP-positive cells were flow sorted
to generate clonal populations. A final diagnostic PCR
was performed to assess for complete removal of the
drug resistance cassettes, and the products were se-
quence verified to ensure that only a single loxP scar
remained (Fig. 7c and d). We generated three clonal
cell lines: two share a common parental cell line prior
to Cre:GFP transfection (rSOX-4 Clone 2-1 and 2-2)
while the other was independently generated (rSOX-4
Clone 1).
We performed RNA-Seq on the clonal cells described
above to assess for gene expression changes. Briefly, RNA
was extracted from the three rSOX-4 deleted cell lines
and from two unmodified S16 cell populations (one was
the parental cell for all three rSOX-4 clonal cell lines).
RNA was subjected to 50-bp, single-end read analysis, and
reads were aligned to the rat (rn5) genome using STAR
[44] and counted using HTSeq [45]. We then used
DESeq2 [46] to identify genes that were differentially
expressed between the rSOX-4 mutant and unmodified
S16 cells. This revealed 198 genes significantly differen-
tially expressed between the two cell populations (Fig. 8a).
Of the 198 genes, six were on the same chromosome (chr
17) as rSOX-4, and only two of these demonstrated de-
creased expression in rSOX-4 mutant S16 cells relative to
unmodified S16 cells: Tubb2b and Gmnn (Table 4). We
focused on these two because of our luciferase data sug-
gesting these regions act as enhancers. To validate these
findings in an independent experimental system, we per-
formed digital droplet PCR (ddPCR) to quantify Tubb2b
and Gmnn expression in rSOX-4 mutant S16 cells and un-
modified S16 cells. We validated the decrease in expres-
sion of Tubb2b using ddPCR (Fig. 8b), but these studies
did not reveal a decrease in Gmnn expression (data not
shown) as observed in our RNA-Seq analysis. Thus, de-
creased Gmnn expression may have been an artifact of the
RNA-Seq experiments. To account for gene expression
changes due to clonal expansion, we also isolated RNA
Table 2 Twenty-two conserved SOX10 consensus sequences
containing SNPs























rSOX-1 through rSOX-9 are conserved monomeric SOX10 consensus sequences
that overlap with SOX10 ChIP-Seq data
rSOX-10 through rSOX-22 are conserved dimeric SOX10 consensus sequences





Coordinates (hg18)a rs Number MAFb
rSOX-1 2.57 8.29 chr2:44834620-44834625 rs3738980 0.3035
rSOX-4 4.83 25.96 chr6:22818474-22818479 rs16886790 0.2001
rSOX-6 0.33 11.01 chr6:98692222-98692227 rs17814604 0.1014
rSOX-22 14.12 4.44 chr16:53169712-53169728 rs1186802 0.4219
aCoordinates for the conserved SOX10 monomeric sites for rSOX-1, −4, and − 6 and the dimeric site for rSOX-22
bMAF is the minor allele frequency from the 1000 Genomes Project [72]
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from five clonal cell populations generated from unmodi-
fied S16 cells, performed RNA-Seq as described above,
and reanalyzed for differential gene expression between
the rSOX-4 mutant S16 cells and all unmodified S16 cell
lines. In agreement with the ddPCR validation studies,
Tubb2b, but not Gmnn, was significantly decreased in ex-
pression in the rSOX-4 mutant cells compared to all un-
modified S16 samples (Additional file 10: Figure S7).
Finally, we performed capped analysis gene expression
(CAGE) [47] on MN1 cells with and without a construct
to over-express SOX10 (see Methods for details; Fogarty
and Antonellis, manuscript in preparation). In the pres-
ence of SOX10, the known SOX10 target genes Mpz and
Mitf show increased reads per million (Fig. 8c and d). Im-
portantly, in the presence of SOX10, Tubb2b shows a dra-
matic increase in expression while Gmnn does not. Taken
together, these results support the conclusion that Tubb2b
is regulated by SOX10 activity at rSOX-4.
rSOX-4 directs LacZ expression in SOX10-positive cells at
E11.5
To determine the physiological relevance of rSOX-4 in
vivo, we assessed the ability of the genomic segment har-
boring the major allele to direct LacZ expression during
mouse development. Because the regulatory activity of
rSOX-4 is dependent on SOX10, we anticipated that
rSOX-4 would demonstrate activity in tissues in which
SOX10 is expressed. Based on the RNA-Seq data indi-
cating that Tubb2b is the target gene of this enhancer,
we selected embryonic day 11.5 (E11.5) due to the
known role of Tubb2b in neuronal migration [22]. We
reasoned that rSOX-4 and Tubb2b may be performing a
similar role in migratory neural crest cells and neural
crest derivatives; Schwann cells are derived from the
neural crest. By E11.5 in mice, the neural tube has







Fig. 6 rSOX-4 and rSOX-22 harbor regulatory SNPs that alter the function of SOX10 consensus sequences. a Each allele of the four rSOX regions
that displayed regulatory activity were assessed in both orientations in S16 cells. Bar colors indicate major allele in the forward orientation (blue),
minor allele in the forward orientation (red), major allele in the reverse orientation (black), and minor allele in the reverse orientation (grey). For
each orientation, the minor allele is expressed relative to the major allele. b Major, minor, and binding-site-deleted (ΔSOX) alleles of rSOX-4 and
rSOX-22 were evaluated for regulatory activity in the more active orientation, in S16 (blue bars) or MN1 (red bars) cells. c-d Major, minor, and
binding-site-deleted (ΔSOX alleles of rSOX-4 and rSOX-22 were evaluated for regulatory activity with and without a construct to express wild-type
SOX10 in MN1 cells (c) or dominant-negative SOX10 in S16 cells (d). Data from untreated cells are in blue and data from cells co-transfected with
a SOX10 expression construct are in red. In all panels, error bars indicate standard deviations. e Sequence variants studied within rSOX-4 and
rSOX-22. The nucleotides surrounding each variant studied [major allele, minor allele, and deleted SOX10 binding site (ΔSOX)] are shown. SOX10
monomeric sites unaffected by the SNP are displayed in green. The SNP within the SOX10 monomeric site is indicated by bold, underlined, and
red text. Deleted nucleotides are indicated by dashes. Each variant name is displayed on the left and corresponds to the sequences tested in
previous panels
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We cloned rSOX-4 upstream of the minimal Hsp68 pro-
moter directing LacZ expression [52] in the reverse orien-
tation because this was the more active orientation in
luciferase assays. The rSOX-4:LacZ transgene was liber-
ated from the plasmid backbone, gel purified, and injected
into mouse zygotes. Zygotes were implanted into pseudo-
pregnant female mice, and embryos were allowed to
develop until E11.5 and then harvested to examine LacZ
expression. We isolated 54 embryos from ten mice and
identified six LacZ positive mice (Fig. 9a-f). Five embryos
demonstrated LacZ staining in the dorsal root ganglia and
migrating melanoblasts (Fig. 9a, b, and d-f), both tissues
in which SOX10 is expressed at E11.5 [53, 54]. A single
embryo displayed ubiquitous blue LacZ staining through-
out the entire embryo, likely a consequence of position ef-
fect (Fig. 9c). These experiments demonstrate that rSOX-
4 is active in SOX10-positive cells during mouse develop-
ment and suggest that Tubb2b plays an important role in
neural crest cell function.
Discussion
The identification and characterization of regulatory vari-
ation (e.g., rSNPs) will improve our understanding of
human biology and disease. To study regulatory variation
in the human genome we developed a computational





Fig. 7 CRISPR-mediated deletion of rSOX-4 in S16 cells. a A cartoon depiction of the rSOX-4 deletion strategy is shown. The 651 bp rSOX-4 enhancer
in unedited cultured rat Schwann (S16) cells is indicated by a blue rectangle. The drug resistance repair cassette is indicated by a green rectangle and
the loxP sequences by orange triangles. Cross lines represent homologous regions for recombination-mediated repair during CRISPR/Cas9-mediated
mutagenesis. Arrows represent the diagnostic PCR primers used in panels B and C, with the name of the corresponding PCR product [wild-type (WT),
5’ Cre, and 3’ Cre] above. b Wild-type (WT) specific PCR was performed on the three Cre:GFP-positive rSOX-4 clonal cell lines (Clone 1, Clone 2-1, Clone
2-2), the parental, pre Cre:GFP transfection (Clone1 – B/N and Clone 2 – B/N) cell lines, and unedited S16 cells. A SOX6-specific PCR was
performed (right panel) as a DNA positive control. c Diagnostic PCR was performed across the 5′ (left panel) and 3′ (right panel) recombination sites
for the same samples indicated in panel B using external (genomically anchored) and internal (repair template anchored) primers. The red arrowhead
indicates the expected size for a single loxP scar. d Sequencing results from the rSOX-4 clonal cell lines in panel C (red arrowhead). The expected
sequence was generated in silico based on proper recombination, Cre excision, and presence of a loxP scar
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and that are conserved among human, mouse, and
chicken. We functionally evaluated a pilot set of 144 con-
served genomic segments in luciferase assays in three cell
lines relevant to the peripheral nerve: Schwann cells,
motor neurons, and muscle cells. We identified 28 (19%
of the 144 elements) putative enhancers, including 13 (9%
of the 144 elements) SNPs that demonstrated significant
allele-specific differences in regulatory activity. We further
assessed our pipeline by separately incorporating consen-
sus sequence information and ChIP-Seq data for SOX10—
a transcription factor essential for Schwann cells. We pri-
oritized 22 conserved genomic segments harboring a SNP
predicted to disrupt a SOX10 binding site and identified
two (9% of the 22 elements) rSNPs with a significant effect
on regulatory activity. Finally, we deeply characterized one
rSNP-containing SOX10 response element by deleting the
region in cultured Schwann cells to identify dysregulated
genes and by generating transient transgenic mice to study
in vivo enhancer activity. Our findings revealed a far-
upstream regulatory variant that effects SOX10 function
at Tubb2b, thus displaying the ability of our approach to
find biologically relevant transcriptional regulatory ele-
ments and associated rSNPs.
The computational and functional studies described
here yielded a large panel of SNPs that reside in highly




































































































Fig. 8 rSOX-4 regulates expression of Tubb2b. a MA plot demonstrating differential gene expression between the rSOX-4 deleted cells and untreated
S16 cells. Each dot represents a gene and red dots indicate a significant difference in expression between the two cell populations (adjusted p < 0.05).
Genes with a positive or negative log2 fold change demonstrated higher or lower expression in the rSOX-4 cells line compared to the untreated S16
cells, respectively. Tubb2b and Gmnn are indicated by arrows. b Digital droplet PCR (ddPCR) was performed to validate RNA-Seq findings for Tubb2b.
Data from the untreated cells are shown by the blue bars, and data from rSOX-4-deleted cells are shown by the red bars. Aldh5a1 was used as a con-
trol gene, which showed no expression changes between the two cell populations. c-f SOX10 increases Tubb2b expression in heterologous cells. MN1
cells were transfected with a construct to express GFP-SOX10, sorted into GFP-positive and GFP-negative populations, and subjected to cap analysis
gene expression (CAGE). CAGE reads mapping to the Mpz (c), Mitf (d), Tubb2b (e), and Gmnn (f) loci were normalized to reads per million and are indi-
cated in red (SOX10-positive cells) and blue (SOX10-negative cells). RefSeq-annotated transcripts at each locus in the mouse genome (mm10) are
shown in black and, in each case, are transcribed from left to right
Table 4 Six genes on chromosome 17 are differentially expressed
in Schwann cells deleted for rSOX-4
Gene p-valuea Fold Changeb Distance from
rSOX-4c
Tubb2b 1.48E-10 −7.41 8.9
Rbm24 0.025 2.63 23
Gmnn 0.042 −1.61 1.9
Etl4 0.044 1.73 47
Mylip 0.044 1.59 20.5
Akr1c19 0.045 2.50 29
aBenjamini-Hochberg adjusted p-value
bFold change calculated relative to unmodified S16 cells (negative values
indicate lower expression in rSOX-4 mutant cells, positive values indicate
higher expression in rSOX-4 mutant cells)
cDistances are given in million basepairs
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cells, and small panels of regulatory SNPs (rSNPs) and
cis-regulatory elements (CREs) useful for investigators
studying peripheral nerve and SOX10 biology. Further-
more, the pipeline developed here is flexible and may ac-
commodate additional CRE information when it becomes
available; for example, we combined our pipeline with pre-
viously unavailable SOX10 ChIP-Seq [39], S16 DNase
hypersensitivity [26], and H3K27 acetylation [43] datasets
to prioritize putative SOX10 binding sites for functional
validation. There are, however, several inherent limitations
to our approach that could be improved upon. First, our
computational predictions of rSNPs relied on non-coding
sequence conservation among diverse vertebrate species.
This limitation is problematic because rSNPs may reside
in less well-conserved genomic regions [55]. Indeed, our
efforts suggest that the employment of strict conservation
analyses does not dramatically enrich for functional regu-
latory elements and associated rSNPs. To address this
problem, one could overlap available SOX10 ChIP-Seq
data [39] with our data set of SOX10 consensus sequences
[26] and study SNPs that map to overlapping genomic se-
quences, regardless of sequence conservation. Second, we
tested a small subset of the 6164 regions predicted by our
computational approach. Recent advances in massively
parallel reporter assays would allow for functional inter-
pretation of most, if not all, of our predictions [56, 57].
The use of a minimally active promoter also restricts our
interpretation because it only allows for detection of major
alleles which direct high levels of reporter activity; using
an active basal promoter could enable the identification of
repressive elements. Finally, the rSNPs identified here
were studied outside of the proper genomic context (i.e., a
small genomic segment surround each SNP allele was
studied for regulatory activity in a vector containing a
luciferase reporter gene). Interestingly, the majority of the
genomic segments and rSNPs that we studied showed
orientation-specific activity and an orientation-specific
effect of the rSNP on regulatory activity. With respect to
the orientation-specific effects, while the classical defin-
ition of an enhancer is that it should act in an orientation-
independent manner, this likely depends on the specific
sequence of the element and how it is cloned into a re-
porter gene vector; indeed, enhancers with orientation-
dependent activity in vitro and in vivo have been reported
[58, 59]. With respect to the orientation-specific effect of
the rSNP, one possible explanation for this is that the pos-
ition of the rSNP in the reporter gene construct has
orientation-specific effects on transcription factor and
transcriptional machinery binding in vitro. While one gen-
omic segment harboring an rSNP (rSOX-4) was evaluated
via CRISPR-mediated deletion of the regulatory element,
future analysis of rSNPs important for peripheral nerve
biology and disease should include studying allele-specific
effects at the endogenous locus in an appropriate cell or
animal model.
Characterization of rSOX-4 via CRISPR/Cas9 [42] medi-
ated deletion revealed Tubb2b as a strong candidate target
gene of this enhancer. TUBB2B is a critical component of
microtubules, and mutations in human TUBB2B result in
polymicrogyria [22]. Interestingly, our transgenic mouse
studies revealed that rSOX-4 directs LacZ expression in
the dorsal root ganglia and migratory melanoblasts. A
a b c
d e f
Fig. 9 rSOX-4 directs in vivo enhancer activity during mouse development. Six transient transgenic mouse embryos were generated to
harbor a transgene with rSOX-4 directing LacZ expression (a-f). Mice were sacrificed at E11.5, and expression patterns were determined
by visual examination under a stereoscope (M =melanoblasts and DRG = dorsal root ganglia). Image cutouts show an enlarged section to
demonstrate melanoblast expression
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mouse strain harboring a GFP transgene reporter inserted
into the endogenous Tubb2b locus has been generated
[60]. The earliest time point the authors looked at was
E14.5, which is after melanoblast migration has completed
[61]; however, the expression patterns are strikingly simi-
lar to our transgenic mouse, as the authors observe GFP
expression within the presumptive spinal cord, in the head
and brain region, and in the dorsal root ganglia. There is
no known role for TUBB2B in the neural crest or, more
specifically, in Schwann cells; however, Tubb2b expression
is highest in migratory neurons [22, 60]. Since rSOX-4 di-
rected LacZ expression in migratory melanoblasts, this
suggests that Tubb2b has a similar, uncharacterized role
in cell migration in melanoblasts and other neural crest
derived cells. Indeed, Schwann cells have a migratory
phase before myelination [62].
Our RNA-Seq, CAGE, and in vitro and in vivo reporter
gene data revealed Tubb2b as the most promising candi-
date target locus of the rSOX-4 enhancer. However,
rSOX-4 resides nearly 9 Mb from Tubb2b and the largest
distance reported between a regulatory element and a tar-
get transcriptional unit is currently 1.7 Mb [63]. Given the
complex domain structure of nuclear organization, it is
feasible that rSOX-4 regulates Tubb2b, but confirming this
will require chromosome conformation capture experi-
ments; until those experiments are complete, other poten-
tial target genes of rSOX-4 should be explored. For
example, a recent release of the human genome (GRCh38)
revealed that rSOX-4 resides within the first intron of a
long non-coding RNA (lncRNA), LOC105374972. There
is no known function of LOC105374972, but it has been
classified as ‘validated’. After converting the coordinates of
this lncRNA from human to rat, we were unable to detect
any RNA-Seq reads corresponding to the lncRNA in our
S16 data. This may be due to the generation of a polyA-
selected RNA library for RNA-Seq; LOC105374972 may
not be polyadenylated [64]. Another possible explanation
for the absence of RNA-Seq reads is that LOC105374972
may not be expressed in Schwann cells. Additional studies
are required to elucidate any functional role of the
lncRNA LOC105374972 in SOX10-positive cells and to
determine if it is regulated by rSOX-4.
Conclusions
In this study, we developed a computational and func-
tional pipeline that identified a small panel of cis-acting
regulatory elements harboring regulatory SNPs (rSNPs).
This pipeline revealed rSNPs in both a transcription factor
independent and dependent manner. While our computa-
tional approach may be less relevant for biological systems
with well-developed genomic data sets, we believe it al-
lows a less-biased strategy for identifying rSNPs important
for developmental stages and tissues for which ChIP-Seq
and related genomic analyses are not feasible. We then
deeply characterized one enhancer that is regulated by
SOX10 (rSOX-4) through CRISPR-mediated deletion and
in vivo transient transgenic mouse reporter experiments.
Through these studies, Tubb2b was identified as a strong
candidate target gene of rSOX-4. While additional experi-
ments are necessary to determine the role of rSOX-4 in
SOX10-positive cells, the rSNP within rSOX-4, the rSOX-
4 enhancer, and the Tubb2b locus all represent excellent
candidate modifiers of neurocristopathies. Additionally,
understanding and characterizing the role of Tubb2b in
neural crest-derived cells—in particular the dorsal root
ganglia and melanoblasts—will provide insight into the
biology of these cell populations.
Methods
PCR and cloning of putative regulatory elements
PCR was performed utilizing primers containing attB1 and
attB2 Gateway cloning (Invitrogen) sequences to amplify a
region surrounding each of the 144 conserved, non-coding
regions with SNPs from human DNA (Additional file 3)
and the 22 SOX10 regions (Table 2). The total amplified
region was based on general conservation using the Phast-
Cons 17-way vertebrate alignment [32]. If a region fell
within a PhastCons track, the primers were designed to
amplify the entire region defined by the track. If a region
did not reside within a PhastCons track, then primers were
designed to amplify a region conserved between human
and mouse only (~ 500 bp). Each amplified region was BP
cloned into pDONR221 using the Gateway cloning tech-
nology (Invitrogen). The regions were sequenced to verify
the SNP allele and absence of additional mutations. These
regions were subsequently LR cloned (Invitrogen) upstream
of a minimal E1B promoter directing luciferase expression
[25] in both the forward (pE1B Forward) and reverse (pE1B
Reverse) orientations. Active regions were converted to the
alternative allele, or SOX10 binding sites were deleted
using site-directed mutagenesis. Mutagenic primers (se-
quences available upon request) were designed, and
mutagenesis was performed on the regions cloned into
pDONR221 using the QuikChange II Mutagenesis Kit
(Agilent Technologies). The resulting constructs were
sequenced to verify specificity and then LR cloned into
pE1B as described above.
Cell culture and transfection for luciferase experiments
We obtained immortalized rat Schwann (S16) cells in
2006 from Richard Quarles (NIH/NINDS) who originally
established these cells [27]. We obtained mouse MN1
cells in 2004 from Kurt Fischbeck (NIH/NINDS), who
obtained them directly from the laboratory that gener-
ated these cells (H. Kim, University of Chicago) [29].
The C2C12 [30] cells were obtained from ATCC (CRL-
1772) in 2011. We routinely test our cells for myco-
plasma contamination. All cell lines were verified for
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authenticity using gene expression experiments includ-
ing RT-PCR and sequencing of products (all three cell
lines), RNA-Seq (S16 cells), and CAGE (MN1 cells). S16
and MN1 cells were cultured at 37 °C in 5% CO2 in
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen)
containing 10% fetal bovine serum (FBS; Invitrogen), 1X
glutamine (Gibco), and 1X Penicillin/Streptavidin (Ther-
moFisher). S16 and MN1 cells were plated at 10,000
cells/well of a 96-well plate. The cells were transfected
the following day using Lipofectamine 2000 (Life Sci-
ences). Each well was transfected with 200 ng of pE1B
[25] plasmid containing the region of interest and 2 ng
of a renilla expression construct. Cells were harvested
48 h after transfection and assessed using the Dual-
Luciferase Reporter system (Promega). Luciferase activ-
ity was normalized to renilla activity, and all regions of
interest were compared to a control vector with no
human genomic insert (‘Empty’ in figures). For tran-
scription factor overexpression assays in S16 and MN1
cells, an additional 100 ng of the overexpression plasmid
was added per well. C2C12 cells were assessed as
described above with the following changes [65]: they
were plated at a concentration of 5000 cells/well in a 96-
well plate, and 24 h after transfection the media was
changed to differentiation media: Dulbecco’s Modified
Eagle Medium (DMEM; Invitrogen) supplemented with
5% horse serum (FBS; Invitrogen), 1X glutamine (Gibco)
, and 1X Penicillin/Streptavidin (ThermoFisher). For all
luciferase assays, at least eight technical replicates across
three biological replicates (n = 24) were performed.
TRANSFAC analysis
The major allele of each SNP was centered within
30 bp of genomic sequence and extracted using the
UCSC Human Genome Browser. The minor allele nu-
cleotide of the candidate rSNP was substituted into the
above sequence to generate the minor allele sequence.
The major and minor allele sequences were then sub-
mitted to TRANSFAC using the Match tool [66]; the
‘vertebrate, non-redundant’ and ‘minimize the sum of
false positive and negative error rates’ options were
used. Results were visually examined and manually fil-
tered to exclude any predicted binding sites that were
identical between the major and minor allele, regardless
of the core or matrix scores.
CRISPR-mediated deletion of rSOX-4
Two guide RNAs (gRNAs) were designed and cloned
into a gRNA expression plasmid (Addgene plasmid
#41824) as previously described [42]. The repair tem-
plate was constructed using Gibson assembly [67] and
cloned into pUC19. The 5′ and 3′ homology arms were
PCR-amplified from S16 genomic DNA, the blasticidin
resistance cassette was PCR amplified from pCMV/Bsd
(ThermoFisher - Cat no. V510-20), and the neomycin
resistance cassette was PCR amplified from the hCas9
backbone (Addgene plasmid #41815) [42]. Wild-type
S16 cells were cultured as described above and plated at
100,000 cells/well in a 6-well dish 24 h prior to transfec-
tion. The cells were transfected with 3 μg of total DNA
[1 μg of hCas9, 1 μg of gRNA expression plasmid, and
1 μg of linearized repair template (~ 1:1:1 M ratio)] using
Lipofectamine 2000. Standard growth media was re-
placed after 4 h of transfection, and the cells were grown
for 72 h at 37 °C and 5% CO2. The growth media was
removed, and selection media (standard growth media
with 4 μg/mL of blasticidin and/or 700 μg/mL of
neomycin) was added. After selection (~ 3 days for blas-
ticidin and ~ 14 days for neomycin) the cells were ex-
panded to a T-75 flask before flow sorting into a 96-well
plate to generate clonal populations. The cells were
gradually expanded over ~ 1 month, genomic DNA was
harvested, and diagnostic PCR was performed using
genomic- and drug-specific primers. The procedure was
repeated to target any remaining wild-type alleles using
a neomycin resistance repair template; however, the
gRNAs had to be reversed due to indels in the remaining
wild-type alleles after blasticidin selection (Additional
file 9: Figure S6; i.e. gRNA1 was used in rSOX-4 Clone
2-B and gRNA2 was used in rSOX-4 Clone 1-B). Add-
itionally, we were unable to amplify the blasticidin repair
template from rSOX-4 Clone 2 following the second
round of clone generation. Double-resistant clones (blas-
ticidin and neomycin) were expanded in T-75 flasks,
transiently transfected with a Cre:GFP expression plas-
mid (Addgene plasmid #13776) to remove the floxed
drug cassettes, and flow sorted to generate clonal GFP-
positive cells.
RNA-Seq analysis of wild-type and rSOX-4 mutant cells
RNA was isolated from the three rSOX-4 mutant S16
lines, two unmodified S16 lines [one parental cell line of
the rSOX-4 mutants (passage 9) and one older passage
(passage 39)], and five clonal expansions of unmodified
S16 cells using TRIzol extraction (ThermoFisher). mRNA
libraries were generated using TruSeq (Illumina) and sub-
jected to 50 bp single-end sequencing on a HiSeq2000.
Two technical replicates of the rSOX-4 mutant and two
unmodified S16 lines cells were pooled and run across two
sequencing lanes which resulted in ~ 21.5 million reads
per cell line. The five clonally expanded S16 cells were
only sequenced once. Read quality was assessed using
FastQC (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/) and reads were aligned to the rat Rnor_5.0
(Ensembl) reference genome using STAR [44]. Default pa-
rameters were used, except only uniquely mapped reads
were allowed (~ 82% of total reads mapped uniquely).
HTSeq [45] was used to count the number of reads per
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gene using default parameters with the stranded reads
function disabled. Finally, differential gene expression be-
tween the rSOX-4 mutant and unmodified S16 cells was
determined using DESeq2 [46]. All programs were run on
the ARCTS flux servers at the University of Michigan. An
identical analysis for the five clonally expanded unmodified
S16 cells was performed as described above. Data for the
two technical and two biological replicates of unmodified
S16 cells are located on NCBI GEO (GSE81709).
Digital droplet PCR
cDNA was synthesized from RNA extracted from the
rSOX-4 mutant and unmodified S16 cells using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Each reaction contained 3.2 μL ultrapure
water, 2 μL 10X random primers, 2 μL 10X RT buffer,
1 μL RNase inhibitor, 0.8 μL dNTPs, 1 μL RNA in 10 μL
of water, and 1 μL MultiScribe reverse transcriptase. The
reaction was incubated for 10 min at 25 °C, then 2 h at
37 °C, then 85 °C for 5 s, and finally held at 4 °C. The
resulting cDNA was diluted 1:333 in ultrapure water
prior to the digital droplet PCR (ddPCR). Each ddPCR
contained 11.5 μL 2X ddPCR supermix (BioRad), 1 μL
FAM probe, 1 μL HEX probe, 6 μL cDNA template (di-
luted 1:333), and 3.5 μL water. FAM probes were
designed against the gene of interest while HEX probes
were against the control gene (Gapdh). Probes and
primers were ordered from IDT PrimeTime as prede-
signed assays for rat except for the FAM probe for
Aldh5a1, which was custom designed using the IDT Pri-
merQuest tool with default parameters for two primers
and one probe. ddPCRs were set up and run per the
manufacturer’s instructions (BioRad), and results were
analyzed using QuantaSoft software to determine the ab-
solute quantification of each gene of interest. Significant
differences between the rSOX 4-mutant and unmodified
S16 cells was performed using a Student’s T-test. Each
cDNA sample was assessed in four technical replicates,
and the average was used in subsequent analyses. For
rSOX-4 mutant cells, one cDNA sample was used for
each mutant line, and all three were combined for the
final analysis. For unmodified S16 cells, three independ-
ent biological replicates were assessed and combined for
the final analysis.
Cap analysis gene expression (CAGE)
The human SOX10 open-reading frame in pDONR221
(Addgene plasmid #24749) was obtained and SOX10 was
cloned into pcDNA-DEST53 using LR Clonase (Thermo-
Fisher) to generate a GFP-SOX10 expression construct.
MN1 cells [29] were plated at a density of 100,000 cells per
mL and transfected with the GFP-SOX10 expression con-
struct using Lipofectamine 2000 (ThermoFisher). After
48 h, cells were harvested, suspended in PBS, and sorted
into GFP-positive and GFP-negative populations using a
SY3200 Cell Sorter (Sony). RNA was isolated from each
cell population using the RNeasy Mini Kit (QIAGEN). A
CAGE library was generated for each sample as described
[47], with modifications made for compatibility with
current generation Illumina sequencing platforms. Each
library was sequenced on an Illumina MiSeq (4 million
reads generated per library). The sequencing data was
analyzed using FastQC (http://www.bioinformatics.babra-
ham.ac.uk/projects/fastqc), filtered using TagDust2 [68],
mapped using BWA [69], clustered using Paraclu [70], and
visualized using BEDtools [71] and the UCSC Genome
Browser [23].
Generation of transient transgenic mice harboring rSOX-
4: LacZ
rSOX-4 was LR cloned upstream of a LacZ reporter gene
directed by the HSP68 minimal promoter [52]. The plasmid
was sequence verified, and the rSOX-4:LacZ transgene frag-
ment was excised from the vector backbone by digestion
with SalI. The transgene was isolated and injected into
mouse zygotes by the University of Michigan transgenic
animal core, and zygotes were implanted into pseudo-
pregnant mice. Pregnant female mice were sacrificed
(CO2 vapor was employed because it is easy to use
and is the recommended choice of the Panel of the
American Veterinarian Medical Association) at embryonic
day 11.5 (E11.5), and embryos were dissected and placed
into 15 mL of ice cold fixative solution: 0.2% glutaralde-
hyde and 2% formaldehyde in PBS. Embryos were fixed
for 20 min on ice and washed three times for 10 min with
wash buffer: 2 mM MgCl2, 5 mM EGTA, and 0.02% NP40
in PBS. After washing, embryos were transferred to a
50 mL conical vial containing ~ 25 mL of LacZ staining
solution: 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, and 1 mg/mL X-gal (Invitrogen) in wash buf-
fer; X-gal was diluted to 50 mg/mL in dimethylformamide
prior to addition to the staining solution. Embryos were
gently rocked at 37 °C overnight in the dark. Embryos
were then washed three times for 10 min each with wash
buffer and imaged using a dissecting scope with QImaging
camera (QICAM FAST1394) and software (Qcapture Pro
Version 6).
Additional files
Additional file 1: Figure S1. A computational pipeline to identify
putative regulatory SNPs. The human, mouse, and chicken genomes were
aligned, and genomic segments that are five base-pairs in length or greater
and identical in all three species were identified to compile a panel of
multiple-species conserved sequences (MCSs). Overlap between the MCS
dataset and validated ‘by-frequency’ SNPs from dbSNP 142 was determined,
and exons were excluded using RefSeq entries. The number of regions in
each resulting dataset are indicated below the label. (AI 1127 kb)
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Additional file 2: List of the 6197 SNPs residing within 6164 conserved,
non-coding sequences. Columns 1 through 3 are BED file formatted
hg18 coordinates of the conserved, non-coding regions. Columns 4
through 6 are BED file formatted hg18 coordinates of the SNPs residing
within the identified regions. The final column is the rs ID number for
each SNP. (TXT 352 kb)
Additional file 3: List of the pilot set of regions and SNPs from
chromosome 21, 22, and X. Columns 1 through 3 are BED file formatted
hg18 coordinates of the conserved, non-coding regions. Columns 4
through 6 are BED file formatted hg18 coordinates of the SNPs residing
within the identified regions. The final column is the rs ID number for
each SNP. (TXT 9 kb)
Additional file 4: Figure S2. Activity of a pilot set of putative regulatory
elements on chromosomes 21, 22, and X in muscle (C2C12) cells. 144
genomic regions containing the major SNP allele were cloned upstream of a
luciferase reporter gene and tested in the forward (blue bars; upper) or
reverse (red bars; lower) orientation in C2C12 cells. The activity of each
genomic segment is expressed relative to a control vector with no insert (first
column) set to “1”. Dashed lines indicate a five-fold increase in activity over
the control vector, and error bars show standard deviations. (AI 1152 kb)
Additional file 5: Figure S3. Seven regions display allele-specific
differences in luciferase activity in muscle (C2C12) cells. (A) The activity
of the major (black bars) and minor (grey bars) alleles of the 21 regions
active in muscle cells (Additional file 4: Figure S2) were evaluated in the
forward (A) or reverse (B) orientation. In both panels, the allele with
higher luciferase activity was set to “100”, error bars represent standard
deviations, bold and underlined text indicate the orientation(s) that
were active in experiments shown in Additional file 4: Figure S2, and
asterisks indicate a significant change in activity (p ≤ 0.05). (AI 1169 kb)
Additional file 6: Figure S4. TRANSFAC predictions of transcription
factor binding sites within elements active in muscle cells. TRANSFAC
was used to assess for allele-specific TFBS predictions between the major
and minor alleles of SNP alleles that had a significant effect on luciferase
activity. Results are shown for seven regions active in C2C12 cells:
SC21-18 (A), SC21-27 (B), SC22-8 (C), SCX-4 (D), SCX-21 (E), SCX-45 (F),
and SCX-67 (G). Thirty base-pairs surrounding each SNP allele was
submitted to TRANSFAC. Dashed arrows indicate the position and
direction of the predicted TFBS, the name of the transcription factor is
indicated above each arrow, and the core and matrix scores are indicated at
the right. Only allele-specific TFBS predictions are displayed. Underlined base
pairs indicate conserved bases, and the SNP alleles are highlighted in red
and bold text. (AI 1331 kb)
Additional file 7: List of the 224 SOX10 consensus sites harboring SNPs.
Columns 1 through 3 are BED file formatted hg18 coordinates of the
conserved, non-coding SOX10 consensus sites. Columns 4 through 6 are
BED file formatted hg18 coordinates of the SNPs residing within the identi-
fied regions. The final column is the rs ID number for each SNP. (TXT 14 kb)
Additional file 8: Figure S5. rSOX-4 overlaps genomic features associated
with enhancers. (A; Top) rSOX-4 (red box) overlaps histone 3 lysine 27
acetylation peaks (H3K27Ac; purple track), SOX10 ChIP-Seq peaks from rat
sciatic nerve (pink track), and S16 DNase hypersensitivity peaks (S16 DNase
HSS; black track). (A; Bottom) Zoomed-out browser from above to show
surrounding rn5 RefSeq genes. Dashed lines to the green bar indicate the
position of rSOX-4 within a gene desert. (B; Top) rSOX-22 (red box) does not
overlap any genomic feature assessed. (B; Bottom) Zoomed-out browser from
above to show surrounding rn5 RefSeq genes. Dashed lines to the green bar
indicate the position of rSOX-22 within a gene desert. In all panels, track
names are at the left, the scale for each track is indicated, and the width of
each browser window is noted at the top (Kb = kilobase pairs and Mb=
megabase pairs). (AI 1851 kb)
Additional file 9: Figure S6. CRISPR cuts all alleles in S16 cells. A wild-
type specific diagnostic PCR was performed on rSOX-4 Clone 1-B and 2-B,
and PCR products were sequenced. (A) A single base pair insertion (yellow
box) of an adenine was identified in the remaining non-recombined alleles
of rSOX-4 Clone 1-B that resides within the gRNA-1 recognition site. (B) A 79
base-pair deletion was detected encompassing the gRNA-2 cut site in rSOX-
4 Clone 2-B. The yellow box represents the expected 5′ sequence, and the
blue box represents the 3′ sequence. In both panels, the rn5 genome
sequence is the expected sequence, and gRNA-1, SOX10 consensus site,
and gRNA-2 are labeled and indicated by lines under the nucleotide
sequences. (AI 1471 kb)
Additional file 10: Figure S7. Tubb2b expression is significantly
reduced in rSOX-4 mutant S16 cells. An MA plot of the mean expression
of every gene (dots) against the log2-fold change is shown. The mean
expression is calculated as the mean of the normalized counts across all
samples, and the log2 fold change is relative to unmodified S16 cells.
Genes above the red line (“0”) indicate higher expression in rSOX-4
mutant cells, and genes below the red line indicate lower expression in
rSOX-4 mutant cells. Red dots indicate genes significantly differentially
expressed between rSOX-4 mutant, and unmodified S16 cells (p < 0.05).
Gmnn and Tubb2b are labeled and indicated by arrows. (AI 17314 kb)
Abbreviations
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